Vical to Manufacture HIV Vaccines for Clinical Evaluation

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Vical to Manufacture HIV Vaccines for Clinical Evaluation by Public-Private Partnership Initiative
  • Vical to receive $4 million under new contract with IPPOX Foundation, funded via a grant from the Bill & Melinda Gates Foundation, to supply plasmid DNA for HIV vaccine clinical trials
  • Builds on recent encouraging results from HIV vaccine clinical studies involving plasmid DNA manufactured by Vical
  • Vical signs Memorandum of Understanding with the Gates Foundation to cooperate on HIV vaccine projects

SAN DIEGO, April 22, 2015 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq: VICL ) today announced that it has entered into a $4 million contract with the IPPOX Foundation to manufacture HIV-antigen plasmid DNA as a component of vaccine regimens to be evaluated in clinical trials for the prevention of HIV infection. IPPOX is a Swiss non-profit foundation that participates in the conduct of HIV vaccine clinical trials under the auspices of the Pox-Protein Public-Private Partnership (P5), funded by the Bill & Melinda Gates Foundation and the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The new contract builds upon Vical's 2010 agreement with IPPOX to manufacture plasmid DNA for HIV vaccine clinical trials and recent encouraging clinical data. 

"Based on the recent HIV vaccine Phase 1 clinical data, in which plasmid DNA, protein, and poxvirus-based vaccines were co-administered, plasmid DNA priming led to higher CD4+ and CD8+ T-cell responses," said Giuseppe Pantaleo, M.D., President of IPPOX and Professor of Medicine, Chief, Division of Immunology and Allergy, Head, Laboratory of AIDS Immunopathogenesis, Department of Medicine at the Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland. "Furthermore, co-administration of plasmid DNA and protein-based HIV vaccines during priming led to early induction of binding and neutralizing antibody responses. We believe that the inclusion of plasmid DNA will be a valuable component of a prophylactic HIV vaccine."

The plasmids manufactured by Vical are expected to be used as priming components of prime/boost vaccine regimens that will be evaluated in additional Phase 1 studies and potentially in a Phase 2b clinical trial to follow. Vical expects material delivery to begin in the fourth quarter of 2015.

Additionally, Vical has signed a Memorandum of Understanding with the Gates Foundation to cooperate on HIV vaccine projects established under the P5 partnership.  P5 seeks to advance and potentially license HIV vaccine candidates that have the potential to achieve a broad public health impact. Core funding for P5 is provided by the foundation and the NIH, and current partners include the foundation, U.S. National Institute of Allergy and Infectious Diseases/Division of AIDS, the HIV Vaccine Trials Network, Novartis Vaccines and Diagnostics, Sanofi Pasteur, the South Africa Medical Research Council, the U.S. Military HIV Research Program (MHRP), GlaxoSmithKline, and Centre Hospitalier Universitaire Vaudois (CHUV).

"Today's announcement provides important validation for the utility of our DNA technology and the strength of our manufacturing expertise," said Vijay B. Samant, Vical's President and CEO. "The results thus far suggest that Vical's plasmid DNA may play an important role in the new vaccine regimens under development to prevent HIV infection. We are proud to be working in collaboration with IPPOX, the Bill & Melinda Gates Foundation and P5 on these initiatives to address an acute unmet medical need throughout the world."

About Vical

Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com .

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include Vical's capabilities to deliver all, if any, of the plasmids by the specified date, and the potential role of plasmid DNA in HIV vaccines. Risks and uncertainties include whether all funding under the contract will be received by the company; whether Vical will be able to perform its obligations under the contract; whether the P5 will continue development of the HIV vaccine candidate; whether planned clinical development of the HIV vaccine candidate will begin when expected, or at all; risks associated with clinical development of vaccine candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Andrew Hopkins (858) 646-1127 Website: www.vical.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 20

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 314

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 23

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 13

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 328

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 12

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 287

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading

Top 5 Most Recently Viewed Articles

AAVantgarde's Professor Auricchio Receives Prestigious Role

Updated Category News Views 177

AAVantgarde's Professor Auricchio Achieves New Milestone MILAN, a milestone moment has arrived for AAVantgarde Bio as Professor Alberto Auricchio, the visionary Founder and Chief Scientific Officer, has been elected President of the European Society of Gene and Cell Therapy. This prestigious appointment recognizes his exceptional contributions and unwavering commitment to...

Continue Reading
How Bitcoin's Drop Affects Strategy Inc (NASDAQ: MSTR) Investors

Updated Category News Views 137

Understanding the Current Market Landscape As recent market trends demonstrate, Strategy Inc (NASDAQ: MSTR) is seeing significant activity. On one hand, the company is evidently reliant on the performance of Bitcoin. With such dependence, the fluctuations in the value of Bitcoin are crucial to the health of MSTR. This situation poses both risks and opportunities for...

Continue Reading
Significant Attorney Departures to Strengthen Association Law Firm

Updated Category News Views 99

Major Attorney Moves to Association Law Group (ALG) In a noteworthy shift within Florida's community association law landscape, several prominent attorneys have transitioned from Becker & Poliakoff to join the ranks of Association Law Group (ALG). Among them, Michael C. Gongora, Lilliana Farinas-Sabogal, and Adam Cervera are recognized for their extensive experience in...

Continue Reading
EQB's Commitment to Sustainability in Financial Services

Updated Category News Views 175

EQB Focuses on Sustainability in Its Latest Report EQB Inc. (TSX: EQB) has recently published a detailed Responsibility Report, highlighting significant strides towards its sustainability commitments. This annual report encapsulates the company's dedication to fostering an environment of innovation within the Canadian banking sector, with a particular focus on enriching...

Continue Reading
BofA's Downgrade of Sandvik: Navigating Market Pressures Ahead

Updated Category News Views 103

BofA Securities dropped a bomb on Sandvik AB back then by downgrading it from Neutral to Underperform. This move sent shockwaves through the trading floor, mainly because they saw some serious trouble brewing in Sandvik’s Machining and Manufacturing Solutions (SMMS) division. Traders were quick to pick up on the whispers about short cycle pressures that could really...

Continue Reading